Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Impact of cyclosporine A concentration on acute graft-vs-host disease incidence after haploidentical hematopoietic cell transplantation.

Stocker N, Duléry R, Battipaglia G, Brissot E, Médiavilla C, Sestili S, Paviglianiti A, Ledraa T, Mohty R, Bazarbachi A, Belhocine R, Vekhoff A, Ruggeri A, Mohty M, Malard F.

Eur J Haematol. 2019 Apr 8. doi: 10.1111/ejh.13233. [Epub ahead of print]

PMID:
30958904
2.

Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation.

Duléry R, Bastos J, Paviglianiti A, Malard F, Brissot E, Battipaglia G, Médiavilla C, Giannotti F, Banet A, de Wyngaert ZV, Ledraa T, Belhocine R, Sestili S, Adaeva R, Lapusan S, Isnard F, Legrand O, Vekhoff A, Rubio MT, Ruggeri A, Mohty M.

Biol Blood Marrow Transplant. 2019 Mar 11. pii: S1083-8791(19)30151-X. doi: 10.1016/j.bbmt.2019.02.025. [Epub ahead of print]

PMID:
30871978
3.

Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematological malignancies carrying multidrug-resistance bacteria.

Battipaglia G, Malard F, Rubio MT, Ruggeri A, Mamez AC, Brissot E, Giannotti F, Dulery R, Joly AC, Baylatry MT, Kossman MJ, Tankovic J, Beaugerie L, Sokol H, Mohty M.

Haematologica. 2019 Feb 7. pii: haematol.2018.198549. doi: 10.3324/haematol.2018.198549. [Epub ahead of print]

4.

Rhino-orbital Mucormycosis presenting as facial cellulitis in a patient with high-risk acute myeloid leukemia in relapse.

Debureaux PE, Paccoud O, Guitard J, Baujat B, Ruggeri A, Battipaglia G, Duléry R, Giannotti F, Malard F, Mohty M, Brissot E.

Curr Res Transl Med. 2019 May;67(2):76-78. doi: 10.1016/j.retram.2019.01.004. Epub 2019 Jan 25. No abstract available.

PMID:
30686650
5.

[Prophylaxis of infections post-allogeneic transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Lewalle P, Pochon C, Michallet M, Turlure P, Brissot E, Paillard C, Puyade M, Roth-Guepin G, Yakoub-Agha I, Chantepie S.

Bull Cancer. 2019 Jan;106(1S):S23-S34. doi: 10.1016/j.bulcan.2018.08.017. Epub 2019 Jan 4. Review. French.

PMID:
30616839
6.

[Post-transplant pulmonary complications: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)].

Buchbinder N, Wallyn F, Lhuillier E, Hicheri Y, Magro L, Farah B, Cornillon J, Duléry R, Vincent L, Brissot E, Yakoub-Agha I, Chevallier P.

Bull Cancer. 2019 Jan;106(1S):S10-S17. doi: 10.1016/j.bulcan.2018.11.006. Epub 2018 Dec 27. French.

PMID:
30595221
7.

CD34+-selected stem cell "Boost" for poor graft function after allogeneic hematopoietic stem cell transplantation.

Mohty R, Brissot E, Battipaglia G, Ruggeri A, Sestili S, Mediavilla C, Belhocine R, Dulery R, Mohty M, Malard F.

Curr Res Transl Med. 2018 Dec 24. pii: S2452-3186(18)30065-5. doi: 10.1016/j.retram.2018.12.003. [Epub ahead of print] No abstract available.

PMID:
30591374
8.

[Post-transplant neurological complications: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)].

Hicheri Y, Buchbinder N, Magro L, Farah B, Zephir H, Brissot E, Yakoub-Agha I, Chevallier P.

Bull Cancer. 2019 Jan;106(1S):S18-S22. doi: 10.1016/j.bulcan.2018.08.015. Epub 2018 Nov 2. French.

PMID:
30392709
9.

Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT.

Brissot E, Labopin M, Ehninger G, Stelljes M, Brecht A, Ganser A, Tischer J, Kröger N, Afanasyev B, Finke J, Elmaagacli A, Einsele H, Mohty M, Nagler A.

Haematologica. 2019 Mar;104(3):524-532. doi: 10.3324/haematol.2017.187450. Epub 2018 Oct 25.

10.

Pathophysiology and classification of iron overload diseases; update 2018.

Brissot P, Troadec MB, Loréal O, Brissot E.

Transfus Clin Biol. 2019 Feb;26(1):80-88. doi: 10.1016/j.tracli.2018.08.006. Epub 2018 Aug 15. Review.

PMID:
30173950
11.

Rare anemias due to genetic iron metabolism defects.

Brissot P, Bernard DG, Brissot E, Loréal O, Troadec MB.

Mutat Res. 2018 Jul - Sep;777:52-63. doi: 10.1016/j.mrrev.2018.06.003. Epub 2018 Jun 22. Review.

12.

Quantitative and functional alterations of 6-sulfo LacNac dendritic cells in multiple myeloma.

Lamarthée B, de Vassoigne F, Malard F, Stocker N, Boussen I, Médiavilla C, Tang R, Fava F, Garderet L, Marjanovic Z, Brissot E, Mohty M, Gaugler B.

Oncoimmunology. 2018 Mar 19;7(7):e1444411. doi: 10.1080/2162402X.2018.1444411. eCollection 2018.

13.

Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.

Picod A, Bonnin A, Battipaglia G, Giannotti F, Ruggeri A, Brissot E, Malard F, Médiavilla C, Belhocine R, Vekhoff A, Gueye MS, Lapusan S, Adaeva R, Isnard F, Legrand O, Baylatry MT, Joly AC, Labopin M, Duléry R, Mohty M.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1471-1475. doi: 10.1016/j.bbmt.2018.02.015. Epub 2018 Mar 1.

PMID:
29477779
14.

Usefulness of ß-D-glucan for diagnosis and follow-up of invasive candidiasis in onco-haematological patients.

Guitard J, Isnard F, Tabone MD, Antignac M, Brissot E, Senghor Y, Petit A, Leverger G, Hennequin C.

J Infect. 2018 May;76(5):483-488. doi: 10.1016/j.jinf.2018.01.011. Epub 2018 Feb 9.

PMID:
29432826
15.

Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors.

Duléry R, Ménard AL, Chantepie S, El-Cheikh J, François S, Delage J, Giannotti F, Ruggeri A, Brissot E, Battipaglia G, Malard F, Belhocine R, Sestili S, Vekhoff A, Delhommeau F, Reman O, Legrand O, Labopin M, Rubio MT, Mohty M.

Biol Blood Marrow Transplant. 2018 May;24(5):1013-1021. doi: 10.1016/j.bbmt.2018.01.005. Epub 2018 Jan 11.

16.

[How to manage EBV reactivation and EBV-PTLD, CMV and human herpesvirus 6 reactivation and infection after allogeneic stem cell transplantation: A report of the SFGM-TC (update)].

Brissot E, Alsuliman T, Gruson B, Hermet E, Tirefort Y, Yakoub-Agha I, Alain S.

Bull Cancer. 2017 Dec;104(12S):S181-S187. doi: 10.1016/j.bulcan.2017.10.022. Epub 2017 Nov 21. Review. French.

PMID:
29169653
17.

Medication adherence among allogeneic hematopoietic stem cell transplant recipients: a pilot single-center study.

Lehrer J, Brissot E, Ruggeri A, Dulery R, Vekhoff A, Battipaglia G, Giannotti F, Fernandez C, Mohty M, Antignac M.

Bone Marrow Transplant. 2018 Feb;53(2):231-233. doi: 10.1038/bmt.2017.233. Epub 2017 Nov 20. No abstract available.

PMID:
29155420
18.

Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.

Brissot E, Labopin M, Stelljes M, Ehninger G, Schwerdtfeger R, Finke J, Kolb HJ, Ganser A, Schäfer-Eckart K, Zander AR, Bunjes D, Mielke S, Bethge WA, Milpied N, Kalhs P, Blau IW, Kröger N, Vitek A, Gramatzki M, Holler E, Schmid C, Esteve J, Mohty M, Nagler A.

J Hematol Oncol. 2017 Jun 24;10(1):130. doi: 10.1186/s13045-017-0498-8.

19.

Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.

Battipaglia G, Ruggeri A, Massoud R, El Cheikh J, Jestin M, Antar A, Ahmed SO, Rasheed W, Shaheen M, Belhocine R, Brissot E, Dulery R, Eder S, Giannotti F, Isnard F, Lapusan S, Rubio MT, Vekhoff A, Aljurf M, Legrand O, Mohty M, Bazarbachi A.

Cancer. 2017 Aug 1;123(15):2867-2874. doi: 10.1002/cncr.30680. Epub 2017 Apr 7.

20.

Current practices for screening, consent and care of related donors in France: Haematopoietic stem cell transplantation coordinator nurses' perceptions.

Polomeni A, Bompoint C, Gomez A, Brissot E, Ruggeri A, Belhocine R, Mohty M.

Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12612. Epub 2016 Dec 6.

PMID:
27922202
21.

Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation.

Clavert A, Peric Z, Brissot E, Malard F, Guillaume T, Delaunay J, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Harousseau JL, Moreau P, Milpied N, Mohty M, Chevallier P.

Biol Blood Marrow Transplant. 2017 Jan;23(1):140-146. doi: 10.1016/j.bbmt.2016.10.011. Epub 2016 Oct 14.

22.

Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Giebel S, Czyz A, Ottmann O, Baron F, Brissot E, Ciceri F, Cornelissen JJ, Esteve J, Gorin NC, Savani B, Schmid C, Mohty M, Nagler A.

Cancer. 2016 Oct;122(19):2941-51. doi: 10.1002/cncr.30130. Epub 2016 Jun 16. Review.

23.

Immune-Mediated Complications after Hematopoietic Stem Cell Transplantation.

Li Z, Rubinstein SM, Thota R, Savani M, Brissot E, Shaw BE, Majhail NS, Mohty M, Savani BN.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1368-1375. doi: 10.1016/j.bbmt.2016.04.005. Epub 2016 Apr 14. Review.

24.

Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival.

Malard F, Labopin M, Chevallier P, Guillaume T, Duquesne A, Rialland F, Derenne S, Peterlin P, Leauté AG, Brissot E, Gregoire M, Moreau P, Saas P, Gaugler B, Mohty M.

Blood. 2016 Apr 7;127(14):1828-35. doi: 10.1182/blood-2015-12-688739. Epub 2016 Feb 22. Erratum in: Blood. 2018 Oct 18;132(16):1726.

25.

Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution.

Brissot E, Rialland F, Cahu X, Strullu M, Corradini N, Thomas C, Blin N, Rialland X, Thebaud E, Chevallier P, Moreau P, Milpied N, Harousseau JL, Mechinaud F, Mohty M.

Bone Marrow Transplant. 2016 Feb;51(2):267-72. doi: 10.1038/bmt.2015.250. Epub 2015 Dec 7.

PMID:
26642337
26.

Transplant to treatment-free remission: the evolving view of 'cure' in chronic myeloid leukemia.

Yong AS, Brissot E, Rubinstein S, Savani BN, Mohty M.

Expert Rev Hematol. 2015 Dec;8(6):785-97. doi: 10.1586/17474086.2015.1087843. Epub 2015 Sep 12. Review.

PMID:
26364871
27.

Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients.

Ruggeri A, Roth-Guepin G, Battipaglia G, Mamez AC, Malard F, Gomez A, Brissot E, Belhocine R, Vekhoff A, Lapusan S, Isnard F, Legrand O, Gozlan J, Boutolleau D, Ledraa T, Labopin M, Rubio MT, Mohty M.

Transpl Infect Dis. 2015 Dec;17(6):822-30. doi: 10.1111/tid.12455. Epub 2015 Nov 25.

PMID:
26354178
28.

Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation.

Battipaglia G, Ruggeri A, Brissot E, Mamez AC, Malard F, Belhocine R, Vekhoff A, Giannotti F, Ledraa T, Labopin M, Rubio MT, Mohty M.

Bone Marrow Transplant. 2015 Dec;50(12):1574-7. doi: 10.1038/bmt.2015.182. Epub 2015 Aug 17. No abstract available.

PMID:
26281029
29.

Which Acute Myeloid Leukemia Patients Should Be Offered Transplantation?

Brissot E, Mohty M.

Semin Hematol. 2015 Jul;52(3):223-31. doi: 10.1053/j.seminhematol.2015.03.001. Epub 2015 Mar 17. Review.

PMID:
26111470
30.

Peripheral Blood Plasmacytoid Dendritic Cells at Day 100 Can Predict Outcome after Allogeneic Stem Cell Transplantation.

Peric Z, Cahu X, Malard F, Brissot E, Chevallier P, Guillaume T, Gregoire M, Gaugler B, Mohty M.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1431-6. doi: 10.1016/j.bbmt.2015.04.003. Epub 2015 Apr 7.

31.

Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma.

Brissot E, Clavert A, Blin N, Roland V, Guillaume T, Dubruille V, Mahe B, Gastinne T, Le Gouill S, Gaugler B, Moreau P, Mohty M.

Leukemia. 2015 Oct;29(10):2098-100. doi: 10.1038/leu.2015.64. Epub 2015 Mar 9. No abstract available.

PMID:
25748683
32.

Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.

Brissot E, Labopin M, Beckers MM, Socié G, Rambaldi A, Volin L, Finke J, Lenhoff S, Kröger N, Ossenkoppele GJ, Craddock CF, Yakoub-Agha I, Gürman G, Russell NH, Aljurf M, Potter MN, Nagler A, Ottmann O, Cornelissen JJ, Esteve J, Mohty M.

Haematologica. 2015 Mar;100(3):392-9. doi: 10.3324/haematol.2014.116954. Epub 2014 Dec 19.

33.

Involvement of the CX3CL1 (fractalkine)/CX3CR1 pathway in the pathogenesis of acute graft-versus-host disease.

Brissot E, Bossard C, Malard F, Braudeau C, Chevallier P, Guillaume T, Delaunay J, Josien R, Gregoire M, Gaugler B, Mohty M.

J Leukoc Biol. 2015 Feb;97(2):227-35. doi: 10.1189/jlb.5HI0714-325R. Epub 2014 Nov 24.

PMID:
25420917
34.

Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation.

Brissot E, Cahu X, Guillaume T, Delaunay J, Ayari S, Peterlin P, Le Bourgeois A, Harousseau JL, Milpied N, Bene MC, Moreau P, Mohty M, Chevallier P.

Ann Hematol. 2015 Apr;94(4):663-9. doi: 10.1007/s00277-014-2259-x. Epub 2014 Nov 21.

PMID:
25409914
35.

Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.

Peterlin P, Delaunay J, Guillaume T, Gastinne T, Mahé B, Dubruille V, Blin N, Le Bourgeois A, Brissot E, Lodé L, Le Gouill S, Moreau P, Mohty M, Chevallier P.

Biol Blood Marrow Transplant. 2015 Jan;21(1):180-4. doi: 10.1016/j.bbmt.2014.08.018. Epub 2014 Aug 28.

36.

Report of disseminated Mycobacterium haemophilum infection after double cord blood allo-SCT.

Brissot E, Gomez A, Aline-Fardin A, Lalande V, Lapusan S, Isnard F, Legrand O, Meynard JL, Rubio MT, Mohty M.

Bone Marrow Transplant. 2014 Oct;49(10):1347-8. doi: 10.1038/bmt.2014.144. Epub 2014 Jul 14. No abstract available.

PMID:
25029233
37.

Increased Th17/Treg ratio in chronic liver GVHD.

Malard F, Bossard C, Brissot E, Chevallier P, Guillaume T, Delaunay J, Mosnier JF, Moreau P, Grégoire M, Gaugler B, Mohty M.

Bone Marrow Transplant. 2014 Apr;49(4):539-44. doi: 10.1038/bmt.2013.215. Epub 2014 Jan 13.

PMID:
24419519
38.

Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas.

de Masson A, Beylot-Barry M, Bouaziz JD, Peffault de Latour R, Aubin F, Garciaz S, d'Incan M, Dereure O, Dalle S, Dompmartin A, Suarez F, Battistella M, Vignon-Pennamen MD, Rivet J, Adamski H, Brice P, François S, Lissandre S, Turlure P, Wierzbicka-Hainaut E, Brissot E, Dulery R, Servais S, Ravinet A, Tabrizi R, Ingen-Housz-Oro S, Joly P, Socié G, Bagot M; French Study Group on Cutaneous Lymphomas and Société Française de Greffe de Moëlle et Thérapie Cellulaire.

Haematologica. 2014 Mar;99(3):527-34. doi: 10.3324/haematol.2013.098145. Epub 2013 Nov 8.

39.

18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study.

Bodet-Milin C, Lacombe M, Malard F, Lestang E, Cahu X, Chevallier P, Guillaume T, Delaunay J, Brissot E, Moreau P, Kraeber-Bodere F, Mohty M.

Bone Marrow Transplant. 2014 Jan;49(1):131-7. doi: 10.1038/bmt.2013.144. Epub 2013 Sep 30.

PMID:
24076550
40.

Increased plasmacytoid dendritic cells and RORγt-expressing immune effectors in cutaneous acute graft-versus-host disease.

Malard F, Bossard C, Brissot E, Chevallier P, Guillaume T, Delaunay J, Mosnier JF, Moreau P, Grégoire M, Gaugler B, Mohty M.

J Leukoc Biol. 2013 Dec;94(6):1337-43. doi: 10.1189/jlb.0513295. Epub 2013 Aug 29.

PMID:
23990625
41.

Effects of bortezomib on the immune system: a focus on immune regulation.

Mohty M, Brissot E, Savani BN, Gaugler B.

Biol Blood Marrow Transplant. 2013 Oct;19(10):1416-20. doi: 10.1016/j.bbmt.2013.05.011. Epub 2013 May 22. Review.

42.

Impact of HDAC inhibitors on dendritic cell functions.

Frikeche J, Peric Z, Brissot E, Grégoire M, Gaugler B, Mohty M.

Exp Hematol. 2012 Oct;40(10):783-91. doi: 10.1016/j.exphem.2012.06.008. Epub 2012 Jun 19. Review.

PMID:
22728031
43.

Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning regimen in children: a single-center experience.

Strullu M, Rialland F, Cahu X, Brissot E, Corradini N, Thomas C, Blin N, Rialland X, Méchinaud F, Mohty M.

Eur J Haematol. 2012 Jun;88(6):504-9. doi: 10.1111/j.1600-0609.2012.01776.x. Epub 2012 Mar 21.

PMID:
22372430
44.

Management of high ferritin in long-term survivors after hematopoietic stem cell transplantation.

Brissot E, Savani BN, Mohty M.

Semin Hematol. 2012 Jan;49(1):35-42. doi: 10.1053/j.seminhematol.2011.10.003. Review.

PMID:
22221783
45.

Impact of valproic acid on dendritic cells function.

Frikeche J, Simon T, Brissot E, Grégoire M, Gaugler B, Mohty M.

Immunobiology. 2012 Jul;217(7):704-10. doi: 10.1016/j.imbio.2011.11.010. Epub 2011 Dec 8.

PMID:
22209114
46.

A novel N491S mutation in the human SLC11A2 gene impairs protein trafficking and in association with the G212V mutation leads to microcytic anemia and liver iron overload.

Bardou-Jacquet E, Island ML, Jouanolle AM, Détivaud L, Fatih N, Ropert M, Brissot E, Mosser A, Maisonneuve H, Brissot P, Loréal O.

Blood Cells Mol Dis. 2011 Dec 15;47(4):243-8. doi: 10.1016/j.bcmd.2011.07.004. Epub 2011 Aug 26.

PMID:
21871825
47.

Impact of the hypomethylating agent 5-azacytidine on dendritic cells function.

Frikeche J, Clavert A, Delaunay J, Brissot E, Grégoire M, Gaugler B, Mohty M.

Exp Hematol. 2011 Nov;39(11):1056-63. doi: 10.1016/j.exphem.2011.08.004. Epub 2011 Aug 18.

PMID:
21856273
48.

Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies.

Malard F, Cahu X, Clavert A, Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Mahe B, Gastinne T, Blin N, Harousseau JL, Moreau P, Miplied N, Le Gouill S, Mohty M.

Biol Blood Marrow Transplant. 2011 Nov;17(11):1698-703. doi: 10.1016/j.bbmt.2011.04.010. Epub 2011 May 3.

49.

Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation.

Peric Z, Cahu X, Chevallier P, Brissot E, Malard F, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahé B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Coste-Burel M, Imbert-Marcille BM, Mohty M.

Bone Marrow Transplant. 2012 Feb;47(2):251-7. doi: 10.1038/bmt.2011.64. Epub 2011 Mar 28.

PMID:
21441959
50.

Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation.

Peric Z, Cahu X, Chevallier P, Brissot E, Malard F, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Milpied N, Coste-Burel M, Imbert-Marcille BM, Mohty M.

Leukemia. 2011 Jun;25(6):932-8. doi: 10.1038/leu.2011.26. Epub 2011 Feb 25.

PMID:
21350556

Supplemental Content

Loading ...
Support Center